Technetium (99mTc) votumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | tumor antigen CTAA16.88 |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.[1] It was developed for the detection of colorectal tumors, but has never been marketed.[2]
The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.[3]
References
- ↑ WHO Drug Information
- ↑ EMA: Public Statement on HumaSPECT Archived 2007-06-10 at the Wayback Machine
- ↑ EMA: Summary of Product Characteristics for HumaSPECT
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.